-Will Also Present at Young Jewish Professionals Life Sciences &
Pharmaceuticals CEO Symposium-
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 10, 2016--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
with a focus on pluripotent stem cell technologies, today announced that
Co-Chief Executive Officer Michael D. West, Ph.D., is participating at
two conferences during the week of November 14.
On Monday, November 14, Dr. West is serving as Chairperson for the Cell
Therapy Track at Terrapinn’s World
Precision Medicine Congress USA 2016. The conference will take place
at the Hyatt Regency Washington on Capitol Hill, in Washington, DC. Dr.
West is also delivering a talk, “Enhancing Autologous Cell Therapies for
the Precision Era,” at 5:10 pm Eastern Time.
On Thursday, November 17, Dr. West is delivering a talk on building a
successful biotechnology company at the Young
Jewish Professionals (YJP) Life Sciences & Pharmaceuticals CEO Symposium,
November 16 and 17 in Midtown Manhattan. This invitation-only forum
features a variety of executives from industry as well as asset
management firms. Dr. West’s talk will focus on lessons learned from
founding Geron, believed to be the first regenerative medicine company,
as well as his time as CEO and Chief Scientific Officer of Advanced Cell
Technology (later renamed Ocata Therapeutics and acquired by Astellas
Pharma earlier this year), and his years with BioTime, which he joined
as CEO in 2007 before transitioning to his current Co-CEO role in 2015.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110006544/en/
Source: BioTime, Inc.
EVC Group, Inc.
Matt Haines, 917-733-9297
Gotham Communications, LLC
Bill Douglass, 646-504-0890